Endocrine Peptide Test Market Report 2026

The endocrine peptide test market size has grown strongly in recent years. It will grow from $9.95 billion in 2025 to $10.88 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to growth in endocrine disorders, expansion of diagnostic laboratories, hormone imbalance awareness, advancements in immunoassay techniques, clinical endocrinology expansion.

The endocrine peptide test market size is expected to see strong growth in the next few years. It will grow to $14.88 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to precision medicine adoption, advanced biomarker research, automation in diagnostic labs, personalized endocrine care, demand for early diagnosis. Major trends in the forecast period include rising demand for hormone disorder diagnostics, increased use of peptide biomarkers, growth in early endocrine disease detection, expansion of laboratory-based specialized testing, focus on accurate hormonal monitoring.

The increasing prevalence of diabetes is expected to support the growth of the endocrine peptide test market in the coming years. Diabetes is a group of metabolic disorders characterized by elevated blood glucose levels. The rise in diabetes cases is driven by factors such as unhealthy dietary habits, sedentary lifestyles, genetic susceptibility, and a growing aging population. Endocrine peptide tests, including hemoglobin A1c, fasting plasma glucose, and C-peptide tests, are widely used in diabetes care to diagnose the disease, monitor glucose control, and evaluate insulin production and sensitivity. For example, in June 2024, the National Health Service (NHS), a UK-based government department, reported a significant increase in the number of individuals under 40 diagnosed with diabetes, rising from 173,166 in 2022 to 216,440 in 2023. This notable increase highlights a concerning trend of rising diabetes prevalence among younger age groups. As a result, the growing burden of diabetes is driving demand in the endocrine peptide test market.

Key players in the endocrine peptide test market are focusing on the development of advanced immunoassay testing systems to enhance the accuracy, sensitivity, and turnaround time of endocrine peptide testing. These systems utilize antibodies to detect and quantify specific peptides in blood or urine samples, offering clinicians critical insights into hormone levels and overall endocrine function. For instance, in July 2023, Siemens Healthineers, a Germany-based healthcare services company, introduced the Atellica CI Analyzer, a compact platform designed for both immunoassay and clinical chemistry testing, including endocrine peptide assays. The system also includes a reproductive endocrinology testing menu, featuring anti-Müllerian hormone (AMH) for assessing ovarian reserve, as well as sFlt-1 and placental growth factor (PlGF) to support the prognosis of preeclampsia. The Atellica CI Analyzer is engineered to deliver consistent, high-quality results with a throughput of up to 1,000 tests per hour, improving laboratory workflow efficiency and flexibility to address evolving testing demands.

In March 2025, Laboratory Corporation of America Holdings, a US-based healthcare diagnostics company, acquired SYNLAB for an undisclosed amount. Through this acquisition, Labcorp seeks to strengthen its footprint in the European diagnostics market by leveraging SYNLAB’s extensive scale and laboratory network to expand access to its specialty testing services, while also exploring procurement and clinical trial synergies. SYNLAB AG is a Germany-based diagnostics provider that offers endocrine peptide testing as part of its broad portfolio of routine and specialized medical diagnostic services.

Major companies operating in the endocrine peptide test market are Siemens AG, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson and Company, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Sciex, Bio-Techne Corporation, Invitae Corporation, ARUP Laboratories, Genova Diagnostics, Boston Heart Diagnostics Corporation, Immunodiagnostic Systems Ltd., Mayo Clinic Laboratories.

North America was the largest region in the endocrine peptide test market in 2025. The regions covered in the endocrine peptide test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the endocrine peptide test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the endocrine peptide test market by increasing costs of imported reagents, assay kits, and laboratory equipment. Diagnostic laboratories and hospitals in developed regions are most affected due to reliance on imported testing components. These tariffs raise testing costs by increasing consumable and instrumentation expenses, limiting testing volumes and routine screening. However, they support domestic production of diagnostic reagents, strengthening regional laboratory supply chains.

The endocrine peptide test market research report is one of a series of new reports that provides endocrine peptide test market statistics, including endocrine peptide test industry global market size, regional shares, competitors with a endocrine peptide test market share, detailed endocrine peptide test market segments, market trends and opportunities, and any further data you may need to thrive in the endocrine peptide test industry. This endocrine peptide test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An endocrine peptide test is a diagnostic procedure used to assess the levels of specific peptides, or small proteins, in blood or urine that are associated with endocrine system function. The main objective of endocrine peptide testing is to identify and monitor endocrine disorders by quantifying particular peptide hormones present in the bloodstream.

The key test types within the endocrine peptide test market include dehydroepiandrosterone sulphate, progesterone, luteinizing hormone, thyroid prolactin, oestradiol, human chorionic gonadotropin, thyroid-stimulating hormone, and others. The dehydroepiandrosterone sulfate (DHEAS) test is a blood-based assay that determines the concentration of DHEAS in the body. Technologies used for these tests include mass spectroscopy, immunoassay, chromatography, nucleic acid-based methods, and others. These tests are utilized by end users such as clinics, healthcare centers, hospitals, and commercial laboratories.

The endocrine peptide test market includes revenues earned by entities by providing services such as diagnostic testing, laboratory analysis, research studies, and clinical evaluations. The market value includes the value of related goods sold by the service provider or included within the service offering. The endocrine peptide test market also includes sales of diagnostic kits, reagents, testing instruments, and laboratory equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.